Posted by Michael Wonder on 17 Oct 2024
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
15 October 2024 - EMA submission is based on data from Phase 3 OASIS development program for elinzanetant.
Bayer has submitted a marketing authorisation application to the EMA for elinzanetant for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy.
